Vesicular nucleotide transporter inhibitors
ω3 fatty acids serve as potent and safe VNUT inhibitors, addressing the limitations of existing inhibitors by providing effective therapeutic outcomes with minimal side effects for a range of diseases.
Patent Information
- Application Number
- JP2020162311
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-09-27
- Filing Date
- 2020-09-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-09-28
AI Technical Summary
Current VNUT inhibitors exhibit limited inhibitory effects at μM concentrations and are associated with significant side effects, necessitating the development of safer and more potent compounds.
The use of specific fatty acids, their pharmaceutically acceptable salts, prodrugs, and metabolites, particularly ω3 polyunsaturated fatty acids, as VNUT inhibitors, which are formulated to provide enhanced inhibitory effects with reduced side effects.
The ω3 fatty acids demonstrate a substantial inhibitory effect on VNUT with high safety and minimal side effects, offering potential therapeutic benefits for various diseases including inflammatory and neuropathic pain, ulcerative colitis, and other conditions.
Smart Images

Figure 0007589972000007 
Figure 0007589972000008 
Figure 0007589972000009
Abstract
Description
[Technical field]
[0001] The present invention relates to vesicular nucleotide transporter inhibitors. [Background technology]
[0002] Vesicular nucleotide transporters (VNUTs) are responsible for transporting ATP to secretory vesicles and are an essential factor in purinergic chemical transmission. In purinergic chemical transmission, ATP loaded in secretory vesicles is released by exocytosis in response to various stimuli and binds to purinergic receptors, thereby transmitting signals. VNUT inhibitors are compounds that can block purinergic chemical transmission by inhibiting the exocytosis of ATP.
[0003] It has been reported that inhibition of VNUT reduces the incidence of inflammatory and neuropathic pain, ulcerative colitis, nonalcoholic hepatitis (NASH), type 2 diabetes, dyslipidemia, chronic inflammation (inflammatory disease), blood coagulation disorder, lower urinary tract dysfunction, itching, infections, etc., and VNUT inhibitors are expected to be used for the treatment and prevention of these diseases. Furthermore, research on purinergic receptors is expected to be applied to Parkinson's disease, Alzheimer's disease, epilepsy, allergic diseases, atopic dermatitis, sepsis, osteoporosis, chronic obstructive pulmonary disease, psoriasis, chronic lung disease, asthma, atherosclerosis, cancer, eye diseases, etc.
[0004] The present inventors and their collaborators have previously investigated the use of acetoacetate (ketone body: VNUT 50% inhibitory concentration (IC 50 ) at approximately 100 μM), glyoxylic acid (keto acid at C2: IC 50 4.1 μM), arachidonic acid (ω6 unsaturated fatty acid: IC 50 However, the inhibitory effects of these compounds were all less than IC 50 However, the concentration of these compounds is at the μM level, and compounds that are effective at even lower concentrations are needed.
[0005] In addition, the present inventors and their collaborators have shown that clodronic acid, a bisphosphonate used to treat osteoporosis, strongly inhibits VNUT (IC 50 It was found that the bisphosphonates were effective in preventing or treating inflammatory bowel disease (Patent Document 2, Non-Patent Document 4). However, serious side effects such as osteonecrosis of the jaw have been reported for some bisphosphonates, and the pharmaceutical and food industries have been demanding compounds that are free of such side effects. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] WO2009 / 116546 A1 [Patent Document 2] WO2017 / 126637 A1 [Non-patent literature]
[0007] [Non-Patent Document 1] Narinobu Juge et al. Neuron 68(1), 99-112, 2010 [Non-Patent Document 2] Miki Hiasa et al. Physiol Rep, 2(6), e12034, 2014 [Non-Patent Document 3] Yuri Kato et al. Biol. Pharm. Bull. 36(11), 1688-1691, 2013 [Non-Patent Document 4] Yuri Kato et al. PNAS doi: 10.1073 / pnas.1704847114, 2017 Summary of the Invention [Problem to be solved by the invention]
[0008] The present invention has been made to solve the above-mentioned problems, and aims to provide a VNUT inhibitor that has a strong VNUT inhibitory effect, is highly safe, and is less likely to cause side effects. [Means for solving the problem]
[0009] The above-mentioned problem can be solved by providing a vesicular nucleotide transporter inhibitor comprising, as an active ingredient, a fatty acid represented by the following formula (1), a pharma- ceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof.
[0010] [ka]
[0011] In formula (1), R is a divalent linear hydrocarbon group having 13 to 19 carbon atoms and containing 2 to 5 carbon-carbon double bonds.
[0012] In this case, the fatty acid is preferably a fatty acid represented by the following formula (2).
[0013] [ka]
[0014] In formula (2), a is an integer of 3 to 6, b is an integer of 1 to 13, and the number of carbon atoms (3a+b+2) is 18 to 24.
[0015] In this case, the fatty acid is 5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (EPA), 6(Z),9(Z),12(Z),15(Z),18(Z)-heneicosapentaenoic acid (HPA), 7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (DPA), 8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (ETA), 4(Z),7(Z),10(Z),13(Z),16(Z),19(Z)-docosahexaenoic acid (DHA), 9(Z),12(Z),15(Z)-octadecatrienoic acid (α-linolenic acid), 6(Z),9(Z),12(Z),15(Z)-Octadecatetraenoic acid (stearidonic acid), 11(Z),14(Z),17(Z)-eicosatrienoic acid, 13(Z),16(Z),19(Z)-docosatrienoic acid, 10(Z),13(Z),16(Z),19(Z)-docosatetraenoic acid (DTA), 9(Z),12(Z),15(Z),18(Z),21(Z)-tetracosapentaenoic acid, 6(Z),9(Z),12(Z),15(Z),18(Z),21(Z)-tetracosahexaenoic acid, 9(Z),12(Z),15(Z),18(Z),21(Z)-tetracosapentaenoic acid, 12(Z),15(Z),18(Z),21(Z)-tetracosatetraenoic acid, and More preferably, it is a compound selected from the group consisting of 15(Z), 18(Z), 21(Z)-tetracosatrienoic acid.
[0016] Among them, the fatty acid is 5(Z),8(Z),11(Z),14(Z),17(Z)-Eicosapentaenoic acid (EPA) 6(Z),9(Z),12(Z),15(Z),18(Z)-heneicosapentaenoic acid (HPA), 7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (DPA), and More preferably, the compound is selected from the group consisting of 8(Z), 11(Z), 14(Z), and 17(Z)-eicosatetraenoic acid (ETA).
[0017] An inhibitor containing the above-mentioned fatty acid or a pharma- ceutically acceptable salt thereof as an active ingredient is one embodiment of the present invention.
[0018] An inhibitor containing the prodrug as an active ingredient is also one embodiment of the present invention. In this case, the prodrug is preferably an ester of the fatty acid and an alcohol.
[0019] In addition, an inhibitor containing the metabolite as an active ingredient is also one embodiment of the present invention. In this case, the metabolite is 20-hydroxy-5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (20-HEPE), 18-hydroxy-5(Z),8(Z),11(Z),14(Z),16(E)-eicosapentaenoic acid (18-HEPE), 15-hydroxy-5(Z),8(Z),11(Z),13(E),17(Z)-eicosapentaenoic acid (15-HEPE), 12-hydroxy-5(Z),8(Z),10(E),14(Z),17(Z)-eicosapentaenoic acid (12-HEPE), 11-hydroxy-5(Z),8(Z),12(E),14(Z),17(Z)-eicosapentaenoic acid (11-HEPE), 9-Hydroxy-5(Z),7(E),11(Z),14(Z),17(Z)-eicosapentaenoic acid (9-HEPE), 8-Hydroxy-5(Z),9(E),11(Z),14(Z),17(Z)-eicosapentaenoic acid (8-HEPE), 5-hydroxy-6(E),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (5-HEPE), 5,6-dihydroxy-8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (5,6-DiHETE), 8,9-dihydroxy-5(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (8,9-DiHETE), 11,12-dihydroxy-5(Z),8(Z),14(Z),17(Z)-eicosatetraenoic acid (11,12-DiHETE), 14,15-dihydroxy-5(Z),8(Z),11(Z),17(Z)-eicosatetraenoic acid (14,15-DiHETE), 17,18-dihydroxy-5(Z),8(Z),11(Z),14(Z)-eicosatetraenoic acid (17,18-DiHETE), 5,12,18-trihydroxy-6(Z),8(E),10(E),14(Z),16(E)-eicosapentaenoic acid (Resolvin E1), 5,18-dihydroxy-6(E),8(Z),11(Z),14(Z),16(E)-eicosapentaenoic acid (Resolvin E2), 17,18-dihydroxy-5(Z),8(Z),11(Z),13(E),15(E)-eicosapentaenoic acid (Resolvin E3), 5,6,15-trihydroxy-7(E),9(E),11(Z),13(E),17(Z)-eicosapentaenoic acid (Lipoxin A5), 17,18-epoxy-5(Z),8(Z),11(Z),14(Z)-eicosatetraenoic acid (17,18-EpETE), 14,15-epoxy-5(Z),8(Z),11(Z),17(Z)-eicosatetraenoic acid (14,15-EpETE), 11,12-epoxy-5(Z),8(Z),14(Z),17(Z)-eicosatetraenoic acid (11,12-EpETE), 8,9-epoxy-5(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (8,9-EpETE), 5,6-epoxy-8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (5,6-EpETE), 16,17-dihydroxy-4(Z),7(Z),10(Z),13(Z),19(Z)-docosapentaenoic acid (16,17-hydroxy DPA), 7,17-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid (7,17-hydroxy DPA), 13,14-dihydroxy-4(Z),7(Z),10(Z),16(Z),19(Z)-docosapentaenoic acid (13,14-hydroxy DPA), 10,11-dihydroxy-4(Z),7(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (10,11-hydroxy DPA), 7,8-dihydroxy-4(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (7,8-hydroxy DPA), 4,5-dihydroxy-7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (4,5-hydroxy DPA), 19,20-epoxy-4(Z),7(Z),10(Z),13(Z),16(Z)-docosapentaenoic acid (19,20-EpDPA), 16,17-epoxy-4(Z),7(Z),10(Z),13(Z),19(Z)-docosapentaenoic acid (16,17-EpDPA), 13,14-epoxy-4(Z),7(Z),10(Z),16(Z),19(Z)-docosapentaenoic acid (13,14-EpDPA), 10,11-epoxy-4(Z),7(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (10,11-EpDPA), 7,8-epoxy-4(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (7,8-EpDPA), 4,5-epoxy-7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (4,5-EpDPA), Prostaglandin E3, Prostaglandin D3, and Preferably, the compound is selected from the group consisting of prostaglandin I3.
[0020] Furthermore, an inhibitor in which the fatty acid, a pharma- ceutical acceptable salt thereof, a prodrug thereof, or a metabolite thereof is administered in a daily dose of 0.0001 to 500 mg / kg body weight is also a preferred embodiment of the present invention. Effect of the Invention
[0021] The vesicular nucleotide transporter inhibitors of the present invention have a strong inhibitory effect on VNUT and are highly safe and less likely to cause side effects. [Brief description of the drawings]
[0022] [Figure 1] 1 is a graph showing the inhibitory effect of various polyunsaturated fatty acids on ATP uptake by VNUT. [Diagram 2] 1 is a graph showing the EPA concentration dependence of the inhibitory effect on ATP uptake by VNUT. [Diagram 3] 1 is a graph showing the inhibitory effect of polyunsaturated fatty acid prodrugs (EPA methyl ester and EPA ethyl ester) on ATP uptake by VNUT. [Figure 4] 1 is a graph showing the inhibitory effect of polyunsaturated fatty acid metabolites (HEPEs) on ATP uptake by VNUT. [Diagram 5] 1 is a graph showing the inhibitory effect of polyunsaturated fatty acid metabolites (12(R)-HEPE, 12(S)-HEPE, and 8(S)-HEPE) on ATP uptake by VNUT. [Figure 6] 1 is a graph showing the inhibitory effect of polyunsaturated fatty acid metabolites (DiHETEs) on ATP uptake by VNUT. [Figure 7] 1 is a graph showing the inhibitory effect of polyunsaturated fatty acid metabolites (EpETEs) on ATP uptake by VNUT. [Figure 8] 1 is a graph showing the inhibitory effect of polyunsaturated fatty acid metabolites (others) on ATP uptake by VNUT. [Figure 9] 1 is a graph showing the chloride ion (Cl-) concentration dependency of the inhibitory effect on ATP uptake by VNUT. [Figure 10] 1 is a graph showing the reversibility of the inhibitory effect on ATP uptake by VNUT. [Figure 11]1 is a graph evaluating the inhibitory effect of EPA on the release of various transmitters from nerve cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023] The vesicular nucleotide transporter (VNUT) inhibitor of the present invention contains, as an active ingredient, a fatty acid represented by the following formula (1), a pharma- ceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof.
[0024] [ka]
[0025] In formula (1), R is a divalent linear hydrocarbon group having 13 to 19 carbon atoms and containing 2 to 5 carbon-carbon double bonds.
[0026] The fatty acid represented by the above formula (1) is a fatty acid having a double bond between the third and fourth carbons from the methyl end of the carbon chain, and is included in what are called omega-3 fatty acids. Omega-3 fatty acids are found in many foods, such as seafood and vegetable oils, and are highly safe.
[0027] In formula (1), R is a divalent linear hydrocarbon group. Therefore, R does not have a branch. The number of carbon atoms contained in R is 13 to 19. That is, the total number of carbon atoms in the fatty acid is 18 to 24. From the viewpoint of VNUT inhibitory activity, the number of carbon atoms contained in R is preferably 15 to 17, more preferably 15. The number of carbon-carbon double bonds contained in R is 2 to 5. From the viewpoint of VNUT inhibitory activity, the number of carbon-carbon double bonds contained in R is preferably 3 or 4. The carbon-carbon double bonds contained in R may be conjugated or non-conjugated, but it is preferable that all double bonds are non-conjugated. When all double bonds are non-conjugated double bonds, the carbon-carbon double bonds are not conjugated with each other, and the carbon-carbon double bonds and the carbon-oxygen double bonds are not conjugated. Between the double bonds, a divalent linear saturated hydrocarbon group such as methylene, ethylene, propylene, or butylene is sandwiched. It is preferable that all of the carbon-carbon double bonds contained in R are in a cis form (Z).
[0028] In a preferred embodiment, the fatty acid is a fatty acid represented by the following formula (2).
[0029] [ka]
[0030] In formula (2), a is an integer of 3 to 6, b is an integer of 1 to 13, and the number of carbon atoms (3a+b+2) is 18 to 24.
[0031] In formula (2), a indicates the number of carbon-carbon double bonds contained in the fatty acid. These carbon-carbon double bonds are linked to each other via a methylene group. In terms of VNUT inhibitory activity, a is preferably 4 or 5. In formula (2), b indicates the number of methylene groups present between the carboxyl group and the carbon-carbon double bond. In terms of VNUT inhibitory activity, b is preferably 2 to 11, more preferably 3 to 8, and even more preferably 3 to 6. In addition, in terms of VNUT inhibitory activity, the number of carbon atoms (3a+b+2) is preferably 20 to 22, and more preferably 20.
[0032] Examples of fatty acids represented by formula (2) include the following. 5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (EPA), 6(Z),9(Z),12(Z),15(Z),18(Z)-heneicosapentaenoic acid (HPA), 7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (DPA), 8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (ETA), 4(Z),7(Z),10(Z),13(Z),16(Z),19(Z)-docosahexaenoic acid (DHA), 9(Z),12(Z),15(Z)-octadecatrienoic acid (α-linolenic acid), 6(Z),9(Z),12(Z),15(Z)-Octadecatetraenoic acid (stearidonic acid), 11(Z),14(Z),17(Z)-eicosatrienoic acid, 13(Z),16(Z),19(Z)-docosatrienoic acid, 10(Z),13(Z),16(Z),19(Z)-docosatetraenoic acid (DTA), 9(Z),12(Z),15(Z),18(Z),21(Z)-tetracosapentaenoic acid, 6(Z),9(Z),12(Z),15(Z),18(Z),21(Z)-tetracosahexaenoic acid, 9(Z),12(Z),15(Z),18(Z),21(Z)-tetracosapentaenoic acid, 12(Z),15(Z),18(Z),21(Z)-tetracosatetraenoic acid, and 15(Z),18(Z),21(Z)-Tetracosatrienoic acid.
[0033] Among these, from the viewpoint of VNUT inhibitory activity, 5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (EPA), 6(Z),9(Z),12(Z),15(Z),18(Z)-heneicosapentaenoic acid (HPA), 7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (DPA) and 8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (ETA) are preferred, with EPA being particularly preferred.
[0034] The fatty acid represented by formula (1) may be in the form of a pharma- ceutically acceptable salt. Specific examples include sodium salt, potassium salt, lithium salt, magnesium salt, calcium salt, aluminum salt, and ammonium salt. Specific examples of ammonium salt include ammonium salt, trimethylammonium salt, diethylammonium salt, tris(hydroxymethyl)methylammonium salt, and bis(2-hydroxyethyl)ammonium salt.
[0035] A prodrug of the fatty acid represented by formula (1) can also be used as the inhibitor of the present invention. The type of prodrug is not particularly limited as long as it is converted into the fatty acid represented by formula (1) or a salt thereof in the body after oral or parenteral administration. Among them, it is preferable that the prodrug is an ester of the fatty acid and an alcohol. The ester is hydrolyzed by esterase in the body and converted into the fatty acid or a salt thereof and an alcohol. In general, esters are often more easily absorbed than fatty acids, so that the prodrug is absorbed in the body in the form of an ester and then converted into a fatty acid with higher inhibitory activity in the body, thereby effectively inhibiting VNUT.
[0036] The alcohol that forms an ester by condensation with the fatty acid is not particularly limited, but is preferably an alcohol having 1 to 20 carbon atoms. The number of carbon atoms of the alcohol is more preferably 10 or less, even more preferably 6 or less, and particularly preferably 3 or less. Although either an aliphatic alcohol or an aromatic alcohol may be used, an aliphatic alcohol is often preferred from the viewpoint of safety. Also, a polyhydric alcohol containing a plurality of hydroxyl groups may be used. Examples of the aliphatic alcohol include methanol, ethanol, 1-propanol, 2-propanol, glycerin, 1-butanol, 2-butanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, and 1-hexanol. Among these, methanol and ethanol are particularly preferred. In the case of a polyhydric alcohol, at least one of the hydroxyl groups may form an ester with the fatty acid represented by formula (1). As the aromatic alcohol, an aryl alkyl alcohol is preferred, and an example of such an alcohol is benzyl alcohol.
[0037] Furthermore, it is also possible to use metabolites of the fatty acids represented by formula (1). For example, the following are examples of metabolites of EPA and DHA: 20-hydroxy-5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (20-HEPE), 18-hydroxy-5(Z),8(Z),11(Z),14(Z),16(E)-eicosapentaenoic acid (18-HEPE), 15-hydroxy-5(Z),8(Z),11(Z),13(E),17(Z)-eicosapentaenoic acid (15-HEPE), 12-hydroxy-5(Z),8(Z),10(E),14(Z),17(Z)-eicosapentaenoic acid (12-HEPE), 11-hydroxy-5(Z),8(Z),12(E),14(Z),17(Z)-eicosapentaenoic acid (11-HEPE), 9-Hydroxy-5(Z),7(E),11(Z),14(Z),17(Z)-eicosapentaenoic acid (9-HEPE), 8-Hydroxy-5(Z),9(E),11(Z),14(Z),17(Z)-eicosapentaenoic acid (8-HEPE), 5-hydroxy-6(E),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (5-HEPE), 5,6-dihydroxy-8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (5,6-DiHETE), 8,9-dihydroxy-5(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (8,9-DiHETE), 11,12-dihydroxy-5(Z),8(Z),14(Z),17(Z)-eicosatetraenoic acid (11,12-DiHETE), 14,15-dihydroxy-5(Z),8(Z),11(Z),17(Z)-eicosatetraenoic acid (14,15-DiHETE), 17,18-dihydroxy-5(Z),8(Z),11(Z),14(Z)-eicosatetraenoic acid (17,18-DiHETE), 5,12,18-trihydroxy-6(Z),8(E),10(E),14(Z),16(E)-eicosapentaenoic acid (Resolvin E1), 5,18-dihydroxy-6(E),8(Z),11(Z),14(Z),16(E)-eicosapentaenoic acid (Resolvin E2), 17,18-dihydroxy-5(Z),8(Z),11(Z),13(E),15(E)-eicosapentaenoic acid (Resolvin E3), 5,6,15-trihydroxy-7(E),9(E),11(Z),13(E),17(Z)-eicosapentaenoic acid (Lipoxin A5), 17,18-epoxy-5(Z),8(Z),11(Z),14(Z)-eicosatetraenoic acid (17,18-EpETE), 14,15-epoxy-5(Z),8(Z),11(Z),17(Z)-eicosatetraenoic acid (14,15-EpETE), 11,12-epoxy-5(Z),8(Z),14(Z),17(Z)-eicosatetraenoic acid (11,12-EpETE), 8,9-epoxy-5(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (8,9-EpETE), 5,6-epoxy-8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (5,6-EpETE), 16,17-dihydroxy-4(Z),7(Z),10(Z),13(Z),19(Z)-docosapentaenoic acid (16,17-hydroxy DPA), 7,17-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid (7,17-hydroxy DPA), 13,14-dihydroxy-4(Z),7(Z),10(Z),16(Z),19(Z)-docosapentaenoic acid (13,14-hydroxy DPA), 10,11-dihydroxy-4(Z),7(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (10,11-hydroxy DPA), 7,8-dihydroxy-4(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (7,8-hydroxy DPA), 4,5-dihydroxy-7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (4,5-hydroxy DPA), 19,20-epoxy-4(Z),7(Z),10(Z),13(Z),16(Z)-docosapentaenoic acid (19,20-EpDPA), 16,17-epoxy-4(Z),7(Z),10(Z),13(Z),19(Z)-docosapentaenoic acid (16,17-EpDPA), 13,14-epoxy-4(Z),7(Z),10(Z),16(Z),19(Z)-docosapentaenoic acid (13,14-EpDPA), 10,11-epoxy-4(Z),7(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (10,11-EpDPA), 7,8-epoxy-4(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (7,8-EpDPA), 4,5-epoxy-7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (4,5-EpDPA), Prostaglandin E3, Prostaglandin D3, and Prostaglandin I3.
[0038] These metabolites may be in the form of pharma- ceutically acceptable salts. Specific examples include sodium salts, potassium salts, lithium salts, magnesium salts, calcium salts, aluminum salts, and ammonium salts. Specific examples of ammonium salts include ammonium salts, trimethylammonium salts, diethylammonium salts, tris(hydroxymethyl)methylammonium salts, and bis(2-hydroxyethyl)ammonium salts.
[0039] The fatty acid represented by formula (1), its pharma- ceutically acceptable salt, its prodrug or its metabolite effectively inhibits VNUT, and it has been revealed that it exhibits a significantly superior effect to arachidonic acid, which is a so-called ω6 fatty acid.
[0040] It has been reported that VNUT knockout mice are less susceptible to inflammatory and neuropathic pain, ulcerative colitis, nonalcoholic hepatitis (NASH), type 2 diabetes, dyslipidemia, chronic inflammation (inflammatory disease), blood coagulation disorder, lower urinary tract dysfunction, itching, infections, etc., so the VNUT inhibitor of the present invention is expected to be used for the treatment and prevention of these diseases. Furthermore, research on purinergic receptors is expected to be applied to Parkinson's disease, Alzheimer's disease, epilepsy, allergic diseases, atopic dermatitis, sepsis, osteoporosis, chronic obstructive pulmonary disease, psoriasis, chronic lung disease, asthma, atherosclerosis, cancer, eye diseases, etc.
[0041] The daily dosage of the fatty acid, its pharma- ceutically acceptable salt, its prodrug, or its metabolite is preferably 0.0001 to 500 mg / kg body weight. The daily dosage is more preferably 0.001 mg / kg body weight or more, and more preferably 0.01 mg / kg body weight or more. On the other hand, the daily dosage is more preferably 200 mg / kg body weight or less, and more preferably 100 mg / kg body weight or less.
[0042] The fatty acid, its pharma- ceutically acceptable salt, its prodrug or its metabolite is highly safe and can be safely administered in large amounts. Therefore, in order to obtain a greater effect, the daily dose is preferably 0.1 mg / kg body weight or more, more preferably 1 mg / kg body weight or more, and particularly preferably 5 mg / kg body weight or more.
[0043] The vesicular nucleotide transporter inhibitor of the present invention may be administered as a fatty acid represented by formula (1), a pharma- ceutical acceptable salt thereof, a prodrug thereof, or a metabolite thereof as it is, but is preferably administered as an oral or parenteral pharmaceutical composition containing the compound. Oral or parenteral pharmaceutical compositions can be prepared using formulation additives available to those skilled in the art, i.e., pharmacologically and pharma- ceutical acceptable carriers.
[0044] Examples of pharmaceutical compositions suitable for oral administration include tablets, capsules, powders, fine granules, granules, liquids, and syrups, while examples of pharmaceutical compositions suitable for parenteral administration include injections, drops, suppositories, inhalants, eye drops, nasal drops, ointments, creams, and patches. Examples of pharmacologically and pharmacy-acceptable carriers used in the manufacture of the pharmaceutical compositions include excipients, disintegrants or disintegration aids, binders, lubricants, coating agents, dyes, diluents, bases, solubilizers, solubilization aids, isotonicity agents, pH regulators, stabilizers, propellants, and adhesives.
[0045] In addition to administering it as a pharmaceutical composition, it can also be ingested by adding it to a beverage or food. The fatty acid represented by formula (1), its pharma- ceutically acceptable salt, its prodrug or its metabolite is highly safe and therefore useful as a food additive. When used as a food additive, it is useful as a food for specified health uses, a food with functional claims, a food with nutrient function claims, etc., which exhibits pharmacological effects derived from VNUT inhibition. EXAMPLES
[0046] Example 1: VNUT inhibitory effect of polyunsaturated fatty acids To verify the inhibitory effect of polyunsaturated fatty acids on VNUT, we measured ATP uptake by VNUT using various polyunsaturated fatty acids. The polyunsaturated fatty acids used were 9(Z),12(Z),15(Z)-octadecatrienoic acid (α-linolenic acid), 6(Z),9(Z),12(Z),15(Z)-Octadecatetraenoic acid (stearidonic acid), 5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (EPA), 6(Z),9(Z),12(Z),15(Z),18(Z)-heneicosapentaenoic acid (HPA), 7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (DPA), 4(Z),7(Z),10(Z),13(Z),16(Z),19(Z)-docosahexaenoic acid (DHA), 11(Z),14(Z),17(Z)-eicosatrienoic acid, 6(Z),9(Z),12(Z),15(Z),18(Z),21(Z)-tetracosahexaenoic acid, 8(Z),11(Z),14(Z),17(Z)-Eicosatetraenoic acid (ETA) and It is arachidonic acid.
[0047] We also measured ATP uptake in VNUT using prodrugs of EPA, namely, EPA methyl ester and EPA ethyl ester.
[0048] In addition, ATP uptake by VNUT was measured in the same manner using the metabolites of EPA. 20-hydroxy-5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (20-HEPE), 18-hydroxy-5(Z),8(Z),11(Z),14(Z),16(E)-eicosapentaenoic acid (18-HEPE), 15-hydroxy-5(Z),8(Z),11(Z),13(E),17(Z)-eicosapentaenoic acid (15-HEPE), 12-hydroxy-5(Z),8(Z),10(E),14(Z),17(Z)-eicosapentaenoic acid (12-HEPE), 11-hydroxy-5(Z),8(Z),12(E),14(Z),17(Z)-eicosapentaenoic acid (11-HEPE), 9-Hydroxy-5(Z),7(E),11(Z),14(Z),17(Z)-eicosapentaenoic acid (9-HEPE), 8-Hydroxy-5(Z),9(E),11(Z),14(Z),17(Z)-eicosapentaenoic acid (8-HEPE), 5-hydroxy-6(E),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (5-HEPE), 5,6-dihydroxy-8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (5,6-DiHETE), 8,9-dihydroxy-5(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (8,9-DiHETE), 14,15-dihydroxy-5(Z),8(Z),11(Z),17(Z)-eicosatetraenoic acid (14,15-DiHETE), 17,18-dihydroxy-5(Z),8(Z),11(Z),14(Z)-eicosatetraenoic acid (17,18-DiHETE), 17,18-epoxy-5(Z),8(Z),11(Z),14(Z)-eicosatetraenoic acid (17,18-EpETE), 14,15-epoxy-5(Z),8(Z),11(Z),17(Z)-eicosatetraenoic acid (14,15-EpETE), 11,12-epoxy-5(Z),8(Z),14(Z),17(Z)-eicosatetraenoic acid (11,12-EpETE), 8,9-epoxy-5(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (8,9-EpETE), 5,12,18-trihydroxy-6(Z),8(E),10(E),14(Z),16(E)-eicosapentaenoic acid (Resolvin E1), 5,6,15-trihydroxy-7(E),9(E),11(Z),13(E),17(Z)-eicosapentaenoic acid (Lipoxin A5) and It is prostaglandin E3.
[0049] In addition, for the above 12-HEPE and 8-HEPE, measurements were performed using their racemic equivalents, but ATP uptake by VNUT was similarly measured using both of these optically active forms (12(S)-HEPE and 12(R)-HEPE) or just one of them (8(S)-HEPE).
[0050] Expression and purification of VNUT, reconstitution into artificial membrane vesicles, and measurement of transport activity were performed according to the method described in Non-Patent Document 4. Membrane fractions in which SLC17A9 (Accession No. NM 001302643, NP 001289572) protein was overexpressed were solubilized and purified by Ni-NTA affinity column chromatography. The purified VNUT protein was incorporated into liposomes to examine whether polyunsaturated fatty acids inhibit VNUT.
[0051] [Reconfiguration] 20 μg of purified protein was mixed with 550 μg of liposomes and left at −80° C. for at least 15 min. The mixture was quickly dissolved and diluted 60-fold with reconstitution buffer containing 20 mM MOPS-Tris (pH 7.0), 150 mM sodium acetate, and 5 mM magnesium acetate. The reconstituted proteoliposomes were pelleted by ultracentrifugation at 200,000 g for 1 h at 4° C. and suspended in 0.2 mL of reconstitution buffer. Asolectin liposomes were prepared as described in Non-Patent Document 4. Soybean lectin (10 mg / mL; Sigma Type IIS) was suspended in a buffer containing 20 mM MOPS-NaOH (pH 7.0) and 1 mM dithiothreitol. The mixture was sonicated with a tip sonicator until clear and stored at −80° C. until use.
[0052] [Transport Assay] 0.3 μg of purified protein incorporated into proteoliposomes, 20 mM MOPS-Tris (pH 7.0), 140 mM potassium acetate, 5 mM magnesium acetate, 10 mM KCl, 2 μM valinomycin, 100 μM [ 3 A reaction mixture (130 μL) consisting of [H]-ATP (0.5 MBq / μmol; Perkin Elmer) and the polyunsaturated fatty acid to be measured (100 nM or 1 μM) was incubated at 27°C. The addition of the potassium ionophore valinomycin resulted in an influx of potassium ions into the liposomes, creating a positive internal membrane potential. Two minutes after the start of the reaction, the transport was terminated by separating the proteoliposomes from the external medium using a centrifugal column containing Sephadex G-50 (fine). [H]-ATP taken up by the proteoliposomes in the eluate was then measured. 3 The radioactivity of [H]-ATP was measured using a liquid scintillation counter (Perkin Elmer). The inhibitory effect of membrane potential-dependent ATP transport activity was calculated by comparing the groups with and without various polyunsaturated fatty acids in the mixture.
[0053] [Data Analysis] Unless otherwise stated, for Example 1, all values are presented as mean ± standard error (n = 4-31). Statistical significance was determined by Student's t-test or analysis of variance (ANOVA). Significance was defined as *P<0.05 and **P<0.01.
[0054] [result] The inhibitory effects of various polyunsaturated fatty acids on VNUT ATP uptake are shown in Figure 1. Among the compounds tested, EPA showed an IC 50 The inhibitory effect of α-linolenic acid was 67 nM, which was the strongest (Figure 2). HPA, DPA, and ETA had a strong inhibitory effect similar to that of EPA. Furthermore, all of the ω3 polyunsaturated fatty acids measured (DHA, α-linolenic acid, stearidonic acid, eicosatrienoic acid, and tetracosahexaenoic acid) showed a superior inhibitory effect to arachidonic acid.
[0055] Furthermore, the inhibitory effects of EPA methyl ester and EPA ethyl ester, which are prodrugs of ω3 polyunsaturated fatty acids, on ATP uptake are shown in Figure 3. These prodrugs also showed more effective inhibitory effects than arachidonic acid.
[0056] The inhibitory effects of 20-HEPE, 18-HEPE, 15-HEPE, 12-HEPE, 11-HEPE, 9-HEPE, 8-HEPE and 5-HEPE, which are metabolites of ω3 polyunsaturated fatty acid (EPA), on ATP uptake are shown in Figure 4. These metabolites also showed more effective inhibitory effects than arachidonic acid. Among them, 5-HEPE, 12-HEPE and 15-HEPE showed large inhibitory effects, and 12-HEPE showed a particularly large inhibitory effect. 12-HEPE shown in Figure 4 is a racemate (±), and the inhibitory effects of 12(R)-HEPE, 12(S)-HEPE and 8(S)-HEPE on ATP uptake are shown in Figure 5. As can be seen from Figure 5, the ATP uptake performance differs depending on the optical isomer, and it was found that 12(R)-HEPE is superior to 12(S)-HEPE. It was also found that 8(S)-HEPE is superior to its racemate and shows a particularly large inhibitory effect.
[0057] The inhibitory effects of 5,6-DiHETE, 8,9-DiHETE, 14,15-DiHETE and 17,18-DiHETE, which are metabolites of ω3 polyunsaturated fatty acid (EPA), on ATP uptake are shown in FIG. 6. The inhibitory effects of 8,9-EpETE, 11,12-EpETE, 14,15-EpETE and 17,18-EpETE, which are metabolites of ω3 polyunsaturated fatty acid (EPA), on ATP uptake are shown in FIG. 7. The inhibitory effects of Resolvin E1, Lipoxin A5 and Prostaglandin E3, which are metabolites of ω3 polyunsaturated fatty acid (EPA), on ATP uptake are shown in FIG. 8. All of them showed a more effective inhibitory effect than arachidonic acid. Among them, dihydroxy compound (DiHETE) and epoxy compound (EpETE) showed a large inhibitory effect. Among them, 8,9-EpETE, 11,12-EpETE and 14,15-EpETE showed particularly large inhibitory effects.
[0058] Example 2: Dependence of VNUT inhibition on chloride ion concentration The VNUT inhibition mode of polyunsaturated fatty acids was investigated using proteoliposomes containing purified VNUT as in Example 1. First, the VNUT inhibitory effects at a physiological chloride ion concentration (10 mM) and at a high chloride ion concentration (100 mM) were compared. By comparing the valinomycin-free group (-Val) and the valinomycin-added group (+Val), the driving force, membrane potential-dependent ATP transport, can be evaluated.
[0059] 130 μL of a reaction mixture (-Val) consisting of 0.3 μg of purified protein incorporated into proteoliposomes, 20 mM MOPS-Tris (pH 7.0), 140 mM potassium acetate, 5 mM magnesium acetate, 10 mM KCl, and 100 μM [3H]-ATP (0.5 MBq / μmol; Perkin Elmer) was incubated at 27°C, and the ATP transport activity was measured for 1 minute from the start of the reaction. In addition, the reaction mixture (-Val) to which 2 μM valinomycin was added (+Val) and the reaction mixture (+Val) to which 1 μM EPA was further added (+1 μM EPA) were also similarly measured. These results are summarized in Figure 9, "10 mM Cl" - "
[0060] In addition, 0.3 μg of purified protein incorporated into proteoliposomes, 20 mM MOPS-Tris (pH 7.0), 50 mM potassium acetate, 5 mM magnesium acetate, 100 mM KCl, and 100 μM [ 3 130 μL of a reaction mixture (-Val) consisting of [H]-ATP (0.5 MBq / μmol; Perkin Elmer) was incubated at 27°C, and the ATP transport activity was measured for 1 minute from the start of the reaction. In addition, the reaction mixture (-Val) to which 2 μM valinomycin was added (+Val) and the reaction mixture (+Val) to which 1 μM EPA was further added (+1 μM EPA) were similarly measured. These results are summarized in Figure 9, "100 mM Cl - "
[0061] The washout experiment was performed at a physiological chloride ion concentration (10 mM) to measure ATP transport activity for 2 minutes from the start of the reaction. Washout(+) is the measurement result using a sample that was mixed with 1 μM EPA and proteoliposomes, pelleted by ultracentrifugation at 4°C, 200,000 g for 1 hour, and then resuspended, while Washout(-) is the measurement result using a sample that was not subjected to this procedure. These results were compared with the above-mentioned "10 mM Cl" without washout. - The results are summarized in Figure 10.
[0062] [Data Analysis] Unless otherwise stated, for Example 2, all values are presented as mean ± standard error (n = 4-11). Statistical significance was determined by Student's t-test or analysis of variance (ANOVA). Significance was defined as *P<0.05 and **P<0.01.
[0063] [result] As shown in FIG. 9, in the presence of EPA, chloride ions (Cl - ATP uptake was significantly inhibited when the concentration of EPA was 10 mM, but was not inhibited at all when the concentration of chloride ions was 100 mM. This suggested the existence of a competitive interaction between EPA and chloride ions. As shown in Figure 10, the effect of EPA was entirely reversible, and activity was fully restored by washing out the compound from the preparation. This result demonstrated that EPA competitively and reversibly inhibits the binding site of VNUT. That is, EPA binds to the chloride ions (Cl) of VNUT in a binding manner that is independent of the binding site of VNUT. - ) It can be said to be a concentration-dependent allosteric modulator.
[0064] Example 3: Inhibitory effect of ATP release from nerve cells According to the method described in Banker GA, Cowan WM. Rat hippocampal neurons in dispersed cell culture, Brain Res 126:397-442 (1977), primary cultures of brain neurons were performed and the inhibitory effect of EPA on the release of ATP and other neurotransmitters (glutamate, aspartate, GABA, and glycine) was examined.
[0065] The Krebs buffer (Low K) consisted of 128 mM NaCl, 1.9 mM KCl, 1.2 mM KH2PO4, 1.3 mM MgSO4, 26 mM NaHCO3, 10 mM D-glucose, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM CaCl2, and 0.2% (wt / vol) BSA. +Neurons were immersed in this buffer for 3 hours, and the release of transmitters was quantified. The results are shown in Figure 11, “Low K + "
[0066] Next, in the same manner as above, Krebs buffer (Low K + ) for 3 h, and then the cells were pretreated with Krebs buffer (High K) consisting of 75 mM NaCl, 55 mM KCl, 1.2 mM KH2PO4, 1.3 mM MgSO4, 26 mM NaHCO3, 10 mM D-glucose, 10 mM HEPES-NaOH (pH 7.4), 2.4 mM CaCl2, and 0.2% (wt / vol) BSA. + After replacing the buffer with Krebs buffer, the release of transmitters was quantified for 20 minutes. The results are shown in "High K + "
[0067] In addition, Krebs buffer (Low K + Neurons were pretreated for 3 hours with 100 nM EPA in Krebs buffer (High K + After replacing the medium with 100 nM EPA, the transmitter release was quantified for 20 minutes. The results are shown in Figure 11 under "100 nM EPA."
[0068] In the above test, ATP was quantified using a microplate reader (Perkin Elmer) by the luciferase luminescence method. Glutamic acid, aspartic acid, GABA, and glycine were fluorescently labeled with orthophthalaldehyde in the presence of 3-mercaptopropionic acid and quantified by ultra-high performance reversed-phase chromatography (ThermoFisher Scientific) using an Accucore-150-C18 column.
[0069] [result] As a result, ATP release was completely inhibited by 100 nM EPA. On the other hand, no significant inhibitory effect was observed with any of the other transmitters. This result indicated that the fatty acid shown in formula (1) selectively inhibits VNUT and can block only ATP release.
Claims
1. A vesicular nucleotide transporter inhibitor comprising a fatty acid represented by the following formula (1), a pharma- ceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof as an active ingredient, the prodrug is an ester of the fatty acid with an aliphatic alcohol having 1 to 20 carbon atoms; The metabolite is 20-hydroxy-5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (20-HEPE), 18-hydroxy-5(Z),8(Z),11(Z),14(Z),16(E)-eicosapentaenoic acid (18-HEPE), 15-hydroxy-5(Z),8(Z),11(Z),13(E),17(Z)-eicosapentaenoic acid (15-HEPE), 12-hydroxy-5(Z),8(Z),10(E),14(Z),17(Z)-eicosapentaenoic acid (12-HEPE), 11-hydroxy-5(Z),8(Z),12(E),14(Z),17(Z)-eicosapentaenoic acid (11-HEPE), 9-Hydroxy-5(Z),7(E),11(Z),14(Z),17(Z)-eicosapentaenoic acid (9-HEPE), 8-Hydroxy-5(Z),9(E),11(Z),14(Z),17(Z)-eicosapentaenoic acid (8-HEPE), 5-hydroxy-6(E),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (5-HEPE), 5,6-dihydroxy-8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (5,6-DiHETE), 8,9-dihydroxy-5(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (8,9-DiHETE), 11,12-dihydroxy-5(Z),8(Z),14(Z),17(Z)-eicosatetraenoic acid (11,12-DiHETE), 14,15-dihydroxy-5(Z),8(Z),11(Z),17(Z)-eicosatetraenoic acid (14,15-DiHETE), 17,18-dihydroxy-5(Z),8(Z),11(Z),14(Z)-eicosatetraenoic acid (17,18-DiHETE), 5,12,18-trihydroxy-6(Z),8(E),10(E),14(Z),16(E)-eicosapentaenoic acid (Resolvin E1), 5,18-dihydroxy-6(E),8(Z),11(Z),14(Z),16(E)-eicosapentaenoic acid (Resolvin E2), 17,18-dihydroxy-5(Z),8(Z),11(Z),13(E),15(E)-eicosapentaenoic acid (Resolvin E3), 5,6,15-trihydroxy-7(E),9(E),11(Z),13(E),17(Z)-eicosapentaenoic acid (Lipoxin A5), 17,18-epoxy-5(Z),8(Z),11(Z),14(Z)-eicosatetraenoic acid (17,18-EpETE), 14,15-epoxy-5(Z),8(Z),11(Z),17(Z)-eicosatetraenoic acid (14,15-EpETE), 11,12-epoxy-5(Z),8(Z),14(Z),17(Z)-eicosatetraenoic acid (11,12-EpETE), 8,9-epoxy-5(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (8,9-EpETE), 5,6-epoxy-8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (5,6-EpETE), 16,17-dihydroxy-4(Z),7(Z),10(Z),13(Z),19(Z)-docosapentaenoic acid (16,17-hydroxy DPA), 7,17-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid (7,17-hydroxy DPA), 13,14-dihydroxy-4(Z),7(Z),10(Z),16(Z),19(Z)-docosapentaenoic acid (13,14-hydroxy DPA), 10,11-dihydroxy-4(Z),7(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (10,11-hydroxy DPA), 7,8-dihydroxy-4(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (7,8-hydroxy DPA), 4,5-dihydroxy-7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (4,5-hydroxy DPA), 19,20-epoxy-4(Z),7(Z),10(Z),13(Z),16(Z)-docosapentaenoic acid (19,20-EpDPA), 16,17-epoxy-4(Z),7(Z),10(Z),13(Z),19(Z)-docosapentaenoic acid (16,17-EpDPA), 13,14-epoxy-4(Z),7(Z),10(Z),16(Z),19(Z)-docosapentaenoic acid (13,14-EpDPA), 10,11-epoxy-4(Z),7(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (10,11-EpDPA), 7,8-epoxy-4(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (7,8-EpDPA), 4,5-epoxy-7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (4,5-EpDPA), Prostaglandin E3, Prostaglandin D3, and A vesicular nucleotide transporter inhibitor which is a compound selected from the group consisting of prostaglandin I3 or a pharma- ceutically acceptable salt thereof (excluding anti-inflammatory agents, tissue protective agents, cardiac remodeling inhibitors, anti-allergic agents, anti-atherosclerotic agents, anti-thrombotic agents, and anti-cancer agents). 【Chemistry 1】 In formula (1), R is a divalent linear hydrocarbon group having 13 to 19 carbon atoms and containing 2 to 5 carbon-carbon double bonds.
2. The inhibitor according to claim 1 , wherein the fatty acid is a fatty acid represented by the following formula (2): 【Chemistry 2】 In formula (2), a is an integer of 3 to 6, b is an integer of 1 to 13, and the number of carbon atoms (3a+b+2) is 18 to 24.
3. The fatty acid is 5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (EPA), 6(Z),9(Z),12(Z),15(Z),18(Z)-heneicosapentaenoic acid (HPA), 7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (DPA), 8(Z),11(Z),14(Z),17(Z)-eicosatetraenoic acid (ETA), 4(Z),7(Z),10(Z),13(Z),16(Z),19(Z)-docosahexaenoic acid (DHA), 9(Z),12(Z),15(Z)-octadecatrienoic acid (α-linolenic acid), 6(Z),9(Z),12(Z),15(Z)-Octadecatetraenoic acid (stearidonic acid), 11(Z),14(Z),17(Z)-eicosatrienoic acid, 13(Z),16(Z),19(Z)-docosatrienoic acid, 10(Z),13(Z),16(Z),19(Z)-docosatetraenoic acid (DTA), 9(Z),12(Z),15(Z),18(Z),21(Z)-tetracosapentaenoic acid, 6(Z),9(Z),12(Z),15(Z),18(Z),21(Z)-tetracosahexaenoic acid, 9(Z),12(Z),15(Z),18(Z),21(Z)-tetracosapentaenoic acid, 12(Z),15(Z),18(Z),21(Z)-tetracosatetraenoic acid, and The inhibitor of claim 2, which is a compound selected from the group consisting of 15(Z), 18(Z), and 21(Z)-tetracosatrienoic acid.
4. The fatty acid is 5(Z),8(Z),11(Z),14(Z),17(Z)-eicosapentaenoic acid (EPA), 6(Z),9(Z),12(Z),15(Z),18(Z)-heneicosapentaenoic acid (HPA), 7(Z),10(Z),13(Z),16(Z),19(Z)-docosapentaenoic acid (DPA), and The inhibitor according to claim 3, which is a compound selected from the group consisting of 8(Z), 11(Z), 14(Z), and 17(Z)-eicosatetraenoic acid (ETA).
5. The inhibitor according to any one of claims 1 to 4, comprising the fatty acid or a pharma- ceutically acceptable salt thereof as an active ingredient.
6. The inhibitor according to any one of claims 1 to 4, comprising the prodrug as an active ingredient.
7. The inhibitor according to any one of claims 1 to 4, comprising the metabolite as an active ingredient.
8. The inhibitor according to any one of claims 1 to 7, wherein the daily dose of the fatty acid, a pharma- ceutically acceptable salt thereof, a prodrug thereof or a metabolite thereof is 0.0001 to 500 mg / kg body weight.
Citation Information
Patent Citations
Excitatory chemical mediator and method for screening thereof
WO2009116546A1
Inflammatory bowel disease preventing agent
WO2017126637A1
